CAS 909395-70-6
:Romosozumab
Description:
Romosozumab is a monoclonal antibody that targets sclerostin, a protein that inhibits bone formation. It is primarily used in the treatment of osteoporosis, particularly in postmenopausal women at high risk of fractures. By inhibiting sclerostin, Romosozumab promotes bone formation and reduces bone resorption, leading to an overall increase in bone mineral density. The substance is administered via subcutaneous injection and has been shown to significantly reduce the risk of vertebral and non-vertebral fractures in clinical trials. Romosozumab's mechanism of action involves the activation of the Wnt signaling pathway, which plays a crucial role in bone metabolism. While it is effective in enhancing bone density, potential side effects may include injection site reactions, headache, and an increased risk of cardiovascular events. As with any medication, it is essential for patients to discuss the benefits and risks with their healthcare provider before starting treatment.
Formula:Unspecified
Synonyms:- Immunoglobulin G2, anti-(human sclerostin) (humanized monoclonal 785A070802 heavy chain), disulfide with humanized monoclonal 785A070802 κ-chain, dimer
- AMG 785
- Immunoglobulin G2, anti-(human sclerostin) (human-mouse monoclonal 785A070802 heavy chain), disulfide with human-mouse monoclonal 785A070802 κ-chain, dimer
- Romosozumab
- Romosozumab-aqqg
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 2 products.
Romosozumab
CAS:<p>Romosozumab (AMG-785) is a humanized monoclonal antibody that binds and inhibits sclerostin, which increases bone formation and decreases bone resorption.</p>Purity:98.9% (SDS-PAGE); 98.2% (SEC-HPLC) - 98.9% (SDS-PAGE); 98.2% (SEC-HPLC)Color and Shape:Liquid
